Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

17 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-03-10

Study Completion Date

2019-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to evaluate the safety profile of Adalimumab for Hidradenitis Suppurativa (HS) participants in normal medical practice.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Post-Marketing Surveillance Study of Adalimumab in Pediatric Chronic Severe Plaque Psoriasis Patients in Korea

NCT03925441

Psoriasis

COMPLETED

Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically

NCT02808975

Hidradenitis Suppurativa (HS)

COMPLETED PHASE4

Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa

NCT00918255

Hidradenitis Suppurativa

COMPLETED PHASE2

Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa

NCT02904902

Hidradenitis Suppurativa

COMPLETED PHASE3

Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa

NCT01468207

Hidradenitis Suppurativa (HS)

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hidradenitis Suppurativa (HS)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants with Hidradenitis suppurativa (HS)

Participants with HS treated with adalimumab (HUMIRA®) in routine clinical practice.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant who are eligible to be treated with adalimumab for HS in accordance with the approved Korean label
* Participant must provide written authorization form to use their personal health data prior to the participating in the study.

Exclusion Criteria

* Participant who are contraindications to adalimumab as listed on the approved Korean label.
* Participant who is participating on other clinical trials.

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No